Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody Best Seller
R&D Systems, part of Bio-Techne | Catalog # BAF357
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human
Applications
Validated:
Western Blot, ELISA Detection (Matched Antibody Pair)
Cited:
Western Blot, Flow Cytometry, ELISA Detection, ELISA Development (Detection), TaqMan Protein Assay
Label
Biotin
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human VEGFR2/KDR/Flk-1
Ala20-Glu764
Accession # AAC16450
Ala20-Glu764
Accession # AAC16450
Specificity
Detects human VEGFR2/KDR/Flk-1 in ELISAs and Western blots. In sandwich immunoassays, less than 0.5% cross-reactivity with recombinant mouse VEGFR2 is observed and less than 0.2% cross-reactivity with recombinant human (rh) VEGFR3 and rhVEGFR1 is observed.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody
Detection of Human VEGFR2/KDR/Flk-1 by ELISA
Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR2/KDR/Flk-1 by ELISA
Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR2/KDR/Flk-1 by ELISA
Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody
Application
Recommended Usage
Western Blot
0.1 µg/mL
Sample: Recombinant Human VEGFR2/KDR/Flk‑1 Fc Chimera (Catalog # 357-KD)
Sample: Recombinant Human VEGFR2/KDR/Flk‑1 Fc Chimera (Catalog # 357-KD)
Human VEGFR2/KDR Sandwich Immunoassay
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGFR2/KDR/Flk-1
VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.
VEGFR2 cDNA encodes a 1356 amino acid (aa) residue precursor protein with a 19 aa residue signal peptide. Mature VEGFR2 is composed of a 745 aa residue extracellular domain, a 25 aa residue transmembrane domain and a 567 aa residue cytoplasmic domain. In contrast to VEGFR1 which binds both PlGF and VEGF with high affinity, VEGFR2 binds VEGF but not PlGF with high affinity.
References
- Ferra, N. and R. Davis-Smyth (1997) Endocrine Reviews 18:4.
Long Name
Vascular Endothelial Growth Factor Receptor 2
Alternate Names
CD309, Flk-1, Flk1, KDR, KRD1, Ly73, VEGF R2
Gene Symbol
KDR
UniProt
Additional VEGFR2/KDR/Flk-1 Products
Product Documents for Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody
Product Specific Notices for Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...